4.7 Article

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Related references

Note: Only part of the references are listed.
Article Immunology

Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity

Kara L. Lynch et al.

Summary: Understanding the kinetics and magnitude of the host antibody response to SARS-CoV-2 is essential for understanding the pathogenesis of COVID-19 and identifying potential therapeutic targets. Research showed that IgM and IgG responses were significantly higher in patients with severe disease compared to those with mild disease, which may have implications for seroprevalence studies, therapeutics, and vaccine development strategies.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Kai Wang et al.

Summary: This study found that specific neutralizing antibody titers against SARS-CoV-2 in patients with COVID-19 were initially low in the first 7-10 days after symptom onset, then gradually increased and peaked at 2-3 weeks. The titers of neutralizing antibodies and IgG levels showed a positive correlation over time, and were also significantly correlated with levels of proinflammatory cytokines.

CLINICAL INFECTIOUS DISEASES (2021)

Review Immunology

Convalescent plasma in Covid-19: Possible mechanisms of action

Manuel Rojas et al.

AUTOIMMUNITY REVIEWS (2020)

Article Medicine, General & Internal

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Article Multidisciplinary Sciences

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Kai Duan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Virology

Treatment with convalescent plasma for COVID-19 patients in Wuhan, China

Mingxiang Ye et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Review Virology

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

Karthick Rajendran et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Editorial Material Hematology

COVID-19 Convalescent Plasma: Now Is the Time for Better Science

Sunny Dzik

TRANSFUSION MEDICINE REVIEWS (2020)

News Item Multidisciplinary Sciences

WILL CORONAVIRUS ANTIBODY TESTS REALLY CHANGE EVERYTHING?

Smriti Mallapaty

NATURE (2020)

Article Biochemistry & Molecular Biology

Antibody responses to SARS-CoV-2 in patients with COVID-19

Quan-Xin Long et al.

NATURE MEDICINE (2020)

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

Article Biochemistry & Molecular Biology

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Quan-Xin Long et al.

NATURE MEDICINE (2020)

Editorial Material Medicine, General & Internal

False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications

Steven Woloshin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Microbiology

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Guillaume Beaudoin-Bussieres et al.

Article Cell Biology

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Jeremie Prevost et al.

CELL REPORTS MEDICINE (2020)

Review Immunology

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity

Ian J. Amanna et al.

IMMUNOLOGICAL REVIEWS (2010)